Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Oramed Pharmaceuticals (ORMP) EBIT (2022 - 2025)

Oramed Pharmaceuticals' EBIT history spans 4 years, with the latest figure at $25.0 million for Q4 2025.

  • For Q4 2025, EBIT changed N/A year-over-year to $25.0 million; the TTM value through Dec 2025 reached $15.6 million, changed N/A, while the annual FY2025 figure was $15.8 million, 573.17% up from the prior year.
  • EBIT reached $25.0 million in Q4 2025 per ORMP's latest filing, up from -$2.4 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $25.0 million in Q4 2025 to a low of -$12.3 million in Q4 2022.
  • Average EBIT over 4 years is -$2.4 million, with a median of -$3.1 million recorded in 2024.
  • Peak YoY movement for EBIT: skyrocketed 205.14% in 2023, then tumbled 51.92% in 2025.
  • A 4-year view of EBIT shows it stood at -$12.3 million in 2022, then surged by 205.14% to $13.0 million in 2023, then tumbled by 123.83% to -$3.1 million in 2024, then skyrocketed by 909.45% to $25.0 million in 2025.
  • Per Business Quant, the three most recent readings for ORMP's EBIT are $25.0 million (Q4 2025), -$2.4 million (Q3 2025), and -$2.5 million (Q2 2025).